AZD1656 is a potent, selective and orally active glucokinase activator with an EC 50 of 60 nM. AZD1656 has the potential for type 2 diabetes research In Vivo AZD1656 (0-9 mg/kg; oral gavage; daily; for 8 weeks; C57BL/6 mice) treatment shows lowered blood glucose and glucose excursion and raised insulin. Liver mRNA levels for various ChREBP target genes including carbohydrate response element binding protein beta isoform (ChREBP-β), G6pc, Pklr, Acly, Acac and Gpd2 are increased by AZD1656 . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: C57BL/6 mice Dosage: 0 mg/kg, 2 mg/kg, 4.5 mg/kg, 9 mg/kg Administration: Oral gavage; daily; for 8 weeks Result: Administered 2 hours before the oral glucose tolerance test, lowered blood glucose and glucose excursion and raised insulin. Form:Solid IC50& Target:EC50: 60 nM (Glucokinase)
All
Chemical Reagents
Biomedicine
Organic raw materials
Inorganic chemical industry
intermediate
Agricultural chemicals
Auxiliaries and catalysts
Fragrances and Flavors
Dyes and Pigments
Daily chemical industry
AZD1656
CAS number：919783-22-5 molecular formula：C24H26N6O5
overview
compound introduction
Specs
| Chinese alias | - | ||
| English alias | (S)-3-(5-(Azetidine-1-carbonyl)pyrazin-2-yloxy)-5-(1-methoxypropan-2-yloxy)-N-(5-methylpyrazin-2-yl)benzamide | BA171838 | 3-((5-(AZETIDIN-1-YLCARBONYL)PYRAZIN-2-YL)OXY)-5-((1S)-2-METHOXY-1-METHYLETHOXY)-N-(5-METHYLPYRAZIN-2-YL)BENZAMIDE | DB14810 | 3-[5- | ||
| CAS number | 919783-22-5 | molecular formula | C24H26N6O5 |
| molecular weight | 478.50 g/mol | Exact mass | ≥98% |
| PSA | 129.000 Ų | logp | 1.3 |
numbering system
No numbering system information yet
physicochemical properties
No physical and chemical property information yet
Safety information
No safety information yet
Production methods and uses
No production method and use information yet
Related
upstream information
No upstream information yet
downstream information
No downstream information yet
MSDS
Found 0 shareMSDS
